Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Navigating payer challenges in rare disease
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...